Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20442852 | 0.86 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23016026 | 0.86 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14564667 | 0.85 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10573143 | 0.84 | CA1 (0.62) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL2987820 | 0.83 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL385451 | 0.83 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL20825298 | 0.83 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21367441 | 0.83 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL7432944 | 0.83 | CA1 (0.60) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17917846 | 0.82 | CA1 (0.59) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | CA1 2167/4885CA2 1427/4885CA7 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.